Product Description
CN-105 is a novel apolipoprotein E-mimetic pentapeptide with excellent preclinical evidence as an acute intracerebral hemorrhage (ICH) therapeutic. CN-105 administration represents an excellent translational candidate as an actue ICH therapeutic due to its safety, dosing feasibility, favorable pharmacokinetics, and evidence of improved neurological recovery. (Sourced from: https://www.medrxiv.org/content/10.1101/2020.10.13.20211417v1)
Mechanisms of Action: APOE Mimetic
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aegis
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cerebral Hemorrhage
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTR20220517 | P2 |
Recruiting |
Cerebral Hemorrhage |
None |
2025-04-29 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/06/2023 |
News Article |
Two New Marvell OCTEON 10 Processors Bring Server-Class Performance to Networking Devices |
|
10/01/2023 |
PubMed |
ApoE Mimetic Peptides as Therapy for Traumatic Brain Injury. |
|
10/01/2022 |
PubMed |
Correction to: CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage (CATCH) Trial. |
|
09/01/2022 |
PubMed |
Prophylactic treatment with CN-105 improves functional outcomes in a murine model of closed head injury. |